Treos Bio, PPD team up for cancer vaccine trial
SAN FRANCISCO & LONDON—September closed with news of an agreement between Treos Bio Limited and Pharmaceutical Product Development LLC (PPD), under which PPD Biotech will manage Treos Bio's first-in-human study of its lead therapeutic cancer vaccine for metastatic colorectal cancer. The study will be held in the United States and Europe.
“We are advancing our lead program for metastatic colorectal cancer because patients face a grim prognosis today with existing treatment options and there is an urgent need to change that,” said Dr. Dong Wei, chief operating officer of Treos Bio. “We are on track to submit an application in the near term to the U.S. Food and Drug Administration to begin for these patients our first human clinical trial, which will transform Treos Bio into a clinical-stage company.”